Last reviewed · How we verify
botulinum toxin Type A (300U)
Botulinum toxin Type A works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.
At a glance
| Generic name | botulinum toxin Type A (300U) |
|---|---|
| Also known as | BOTOX® |
| Sponsor | Allergan |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
By inhibiting acetylcholine release, botulinum toxin Type A reduces muscle spasms and contractions, providing relief for conditions such as blepharospasm and cervical dystonia.
Approved indications
Common side effects
Key clinical trials
- The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures (NA)
- BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence (PHASE2)
- A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis (PHASE3)
- Efficacy and Safety of MEDITOXIN® in Cervical Dystonia (PHASE3)
- OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity (PHASE3)
- Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients (PHASE2)
- Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients (PHASE1, PHASE2)
- Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |